Inhaltsbereich
| 226 Einträge | « ‹ 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 › » |
Seite 4 / 12
 Druckansicht
|
| Landomycins as glutathione-depleting agents and natural fluorescent probes for cellular Michael adduct-dependent quinone metabolism. |
| Terenzi A, La Franca M, van Schoonhoven S, Panchuk R, Martínez Á, Heffeter P, Gober R, Pirker C, Vician P, Kowol CR, Stoika R, Salassa L, Rohr J, Berger W |
| Communications chemistry. 2021 Nov 25. doi: 10.1038/s42004-021-00600-4. pii: 10.1038/s42004-021-00600-4. pmc: PMC9814637 |
| PMID: 36697631 |
| Influence of the Fatty Acid Metabolism on the Mode of Action of a Cisplatin(IV) Complex with Phenylbutyrate as Axial Ligands. |
| Mendrina T, Poetsch I, Schueffl H, Baier D, Pirker C, Ries A, Keppler BK, Kowol CR, Gibson D, Grusch M, Berger W, Heffeter P |
| Pharmaceutics. 2023 Feb 16. doi: 10.3390/pharmaceutics15020677. pii: pharmaceutics15020677 |
| PMID: 36839999 |
| A novel EGFR inhibitor acts as potent tool for hypoxia-activated prodrug systems and exerts strong synergistic activity with VEGFR inhibition in vitro and in vivo. |
| Caban M, Koblmueller B, Groza D, Schueffl HH, Terenzi A, Tolios A, Mohr T, Mathuber M, Kryeziu K, Jaunecker C, Pirker C, Keppler BK, Berger W, Kowol CR, Heffeter P |
| Cancer letters. 2023 May 19. doi: 10.1016/j.canlet.2023.216237. pii: S0304-3835(23)00188-X |
| PMID: 37211067 |
| Aberrant DNA Methylation, Expression, and Occurrence of Transcript Variants of the ABC Transporter in Breast Cancer. |
| Zappe K, Kopic A, Scheichel A, Schier AK, Schmidt LE, Borutzki Y, Miedl H, Schreiber M, Mendrina T, Pirker C, Pfeiler G, Hacker S, Haslik W, Pils D, Bileck A, Gerner C, Meier-Menches S, Heffeter P, Cichna-Markl M |
| Cells. 2023 May 24. doi: 10.3390/cells12111462. pii: cells12111462 |
| PMID: 37296582 |
| Primary and hTERT-Transduced Mesothelioma-Associated Fibroblasts but Not Primary or hTERT-Transduced Mesothelial Cells Stimulate Growth of Human Mesothelioma Cells. |
| Ries A, Slany A, Pirker C, Mader JC, Mejri D, Mohr T, Schelch K, Flehberger D, Maach N, Hashim M, Hoda MA, Dome B, Krupitza G, Berger W, Gerner C, Holzmann K, Grusch M |
| Cells. 2023 Aug 5. doi: 10.3390/cells12152006. pii: cells12152006 |
| PMID: 37566084 |
| Krebs von den Lungen 6 (KL-6) is a novel diagnostic and prognostic biomarker in pleural mesothelioma. |
| Stockhammer P, Baumeister H, Ploenes T, Bonella F, Theegarten D, Dome B, Pirker C, Berger W, Hegedüs L, Baranyi M, Schuler M, Deshayes S, Bölükbas S, Aigner C, Blanquart C, Hegedüs B |
| Lung cancer (Amsterdam, Netherlands). 2023 Sep 7. doi: 10.1016/j.lungcan.2023.107360. pii: S0169-5002(23)00898-X |
| PMID: 37713954 |
| Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer in the Real-World Setting in Central Europe: The INSIGHT Study. |
| Ramlau R, Cufer T, Berzinec P, Dziadziuszko R, Olszewski W, Popper H, Bajcic P, Dušek L, Zbozinkova Z, Pirker R |
| Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2015 Aug 21. doi: 10.1097/JTO.0000000000000621. pii: 01243894-201509000-00019 |
| PMID: 26291014 |
| Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. |
| Gnant M, Pfeiler G, Dubsky PC, Hubalek M, Greil R, Jakesz R, Wette V, Balic M, Haslbauer F, Melbinger E, Bjelic-Radisic V, Artner-Matuschek S, Fitzal F, Marth C, Sevelda P, Mlineritsch B, Steger GG, Manfreda D, Exner R, Egle D, Bergh J, Kainberger F, Talbot S, Warner D, Fesl C, Singer CF |
| Lancet (London, England). 2015 May 31. pii: S0140-6736(15)60995-3. doi: 10.1016/S0140-6736(15)60995-3 |
| PMID: 26040499 |
| Adjuvant chemotherapy in patients with completely resected non-small cell lung cancer. |
| Pirker R |
| Translational lung cancer research. 2015 Mar 25. doi: 10.3978/j.issn.2218-6751.2014.09.13. pii: tlcr-03-05-305. pmc: PMC4367797 |
| PMID: 25806316 |
| Epidermal growth factor receptor-directed monoclonal antibodies in nonsmall cell lung cancer: an update. |
| Pirker R |
| Current opinion in oncology. 2015 Feb 4. doi: 10.1097/CCO.0000000000000162 |
| PMID: 25636162 |
| Perspectives of novel imaging techniques for staging, therapy response assessment, and monitoring of surveillance in lung cancer: summary of the Dresden 2013 Post WCLC-IASLC State-of-the-Art Imaging Workshop. |
| Henzler T, Goldstraw P, Wenz F, Pirker R, Weder W, Apfaltrer P, Meyer M, Buesing K, Crino L, Fennell D, Fink C, Grunenwald D, Manegold C, Pilz L, Schoenberg SO, Suresh S, Vansteenkiste J, Voigt W, Wängler B, Schmid-Bindert G |
| Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2015 Jan 23. doi: 10.1097/JTO.0000000000000412. pii: 01243894-201502000-00004 |
| PMID: 25611226 |
| Relationship between EGFR expression, EGFR mutation status, and the efficacy of chemotherapy plus cetuximab in FLEX study patients with advanced non-small-cell lung cancer. |
| Douillard JY, Pirker R, O'Byrne KJ, Kerr KM, Störkel S, von Heydebreck A, Grote HJ, Celik I, Shepherd FA |
| Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2014 Apr 11. doi: 10.1097/JTO.0000000000000141 |
| PMID: 24662454 |
| Mechanism of reaction of chlorite with mammalian heme peroxidases. |
| Jakopitsch C, Pirker KF, Flemmig J, Hofbauer S, Schlorke D, Furtmüller PG, Arnhold J, Obinger C |
| Journal of inorganic biochemistry. 2014 Feb 28. pii: S0162-0134(14)00061-0. doi: 10.1016/j.jinorgbio.2014.02.010. pmc: PMC4003552 |
| PMID: 24632343 |
| Significance of TP53 mutations as predictive markers of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer. |
| Ma X, Rousseau V, Sun H, Lantuejoul S, Filipits M, Pirker R, Popper H, Mendiboure J, Vataire AL, Le Chevalier T, Soria JC, Brambilla E, Dunant A, Hainaut P |
| Molecular oncology. 2014 Jan 15. pii: S1574-7891(13)00187-7. doi: 10.1016/j.molonc.2013.12.015 |
| PMID: 24495481 |
| Three Metachronous Osteosarcomas within 22 Years without Pulmonary Metastases: A Case Report and Review of the Literature. |
| Pirker-Frühauf UM, Friesenbichler J, Rabitsch K, Liegl-Atzwanger B, Bauernhofer T, Windhager R, Leithner A |
| Case reports in orthopedics. 2013 Dec 25. doi: 10.1155/2013/197287. pmc: PMC3886224 |
| PMID: 24455368 |
| Overcoming resistance to first generation EGFR TKIs with cetuximab in combination with chemotherapy in an EGFR mutated advanced stage NSCLC patient. |
| Pircher A, Manzl C, Fiegl M, Popper H, Pirker R, Hilbe W |
| Lung cancer (Amsterdam, Netherlands). 2013 Dec 25. pii: S0169-5002(13)00572-2. doi: 10.1016/j.lungcan.2013.12.007 |
| PMID: 24412619 |
| Novel drugs against non-small-cell lung cancer. |
| Pirker R |
| Current opinion in oncology. 2014 Feb 7. doi: 10.1097/CCO.0000000000000056 |
| PMID: 24406751 |
| Meta-analysis of individual patient data from randomized trials of chemotherapy plus cetuximab as first-line treatment for advanced non-small cell lung cancer. |
| Pujol JL, Pirker R, Lynch TJ, Butts CA, Rosell R, Shepherd FA, Vansteenkiste J, O'Byrne KJ, de Blas B, Heighway J, von Heydebreck A, Thatcher N |
| Lung cancer (Amsterdam, Netherlands). 2013 Nov 16. pii: S0169-5002(13)00517-5. doi: 10.1016/j.lungcan.2013.11.006 |
| PMID: 24332319 |
| EGFR-directed monoclonal antibodies in non-small cell lung cancer. |
| Pirker R |
| Targeted oncology. 2013 Jan 9. doi: 10.1007/s11523-012-0244-7 |
| PMID: 23300028 |
| EGFR-directed monoclonal antibodies in non-small cell lung cancer: how to predict efficacy? |
| Pirker R |
| Translational lung cancer research. 2015 Mar 25. doi: 10.3978/j.issn.2218-6751.2012.10.09. pii: tlcr-01-04-269. pmc: PMC4367547 |
| PMID: 25806192 |
| 226 Einträge | « ‹ 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 › » |
Seite 4 / 12
Druckansicht
|
Schnellinfo
-- Initiative Krebsforschung / Krebsforschungslauf
-- Cancer Care
-- Kliniken und Partner
-- CCC Cancer School
-- Young CCC
-- CCC Tumorboards
-- CCC Forschungscluster
-- CCC Units
-- CCC Platforms
-- SOPs / Leitlinien
-- Kontakt
-- Cancer Care
-- Kliniken und Partner
-- CCC Cancer School
-- Young CCC
-- CCC Tumorboards
-- CCC Forschungscluster
-- CCC Units
-- CCC Platforms
-- SOPs / Leitlinien
-- Kontakt
Featured
